|
Zacks Rating on Rockwell Medical, Inc. - American Trade Journal |
 |
|
As much as 4 analysts have advised buy on Rockwell Medical, Inc. (NASDAQ:RMTI) with an average broker rating of 2. Research Analysts at Zacks has the shares a rating of 3, which implies that the firms recommendation is Neutral on the company.
Rockwell Medical, Inc. (NASDAQ:RMTI) stock has received a short term price target of $ 16.25 from 4 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $9.18. The higher estimate of target price is $26 , while the lower price target estimate is $4 Currently the company Insiders own 5.5% of Rockwell Medical, Inc. Company shares. In the past six months, there is a change of 0% in the total insider ownership. Institutional Investors own 33.9% of Company shares. During last 3 month period, 24.07% of total institutional ownership has changed in the company shares.
Rockwell Medical, Inc. (NASDAQ:RMTI) : On Monday heightened volatility was witnessed in Rockwell Medical, Inc. (NASDAQ:RMTI) which led to swings in the share price. The shares opened for trading at $16.06 and hit $16.6 on the upside , eventually ending the session at $16.51, with a gain of 1.85% or 0.3 points. The heightened volatility saw the trading volume jump to 730,082 shares. The 52-week high of the share price is $18.04 and the company has a market cap of $828 million. The 52-week low of the share price is at $8.095 . The company shares have rallied 36.33% from its 1 Year high price. On Jun 25, 2015, the shares registered one year high at $18.04 and the one year low was seen on Dec 15, 2014. The 50-Day Moving Average price is $12.87 and the 200 Day Moving Average price is recorded at $10.97. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.
|